Aims: The aim of these studies was to validate the analytical performance of a cell cycle progression (CCP) gene signature that provides prognostic information for early stage lung adenocarcinomas. Materials & methods: Formalin-fixed paraffin-embedded (FFPE) lung resections were evaluated by quantitative RT-PCR for the expression of 31 target and 15 housekeeper genes comprising the CCP score. Results: The signature had a standard deviation (SD) of 0.06 score units and a dynamic range spanning CCP scores between -13 and 14. The average amplicon efficiencies for target and housekeeper genes were 107% and 105%, respectively. All but one amplicon had a SD <0.5 C_T. Conclusion: These studies demonstrate that the gene signature is robust and reproducible, making it suitable for use in a clinical setting.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest.

References

1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9–29 (2014).
MedlineGoogle Scholar
2 Chansky K, Sculier JP, Crowley JJ et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J. Thorac. Oncol. 4(7), 792–801 (2009).
MedlineGoogle Scholar
3 Tsuboi M, Ohira T, Saji H et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann. Thorac. Cardiovasc. Surg. 13(2), 73–77 (2007).
MedlineGoogle Scholar
4 Crino L, Weder W, Van Meerbeeck J, Felip E, Group EGW. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v103–v115 (2010).
MedlineGoogle Scholar
5 Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552–3559 (2008).
MedlineGoogle Scholar
6 Pisters KM, Evans WK, Azzoli CG et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J. Clin. Oncol. 25(34), 5506–5518 (2007).
MedlineGoogle Scholar
7 Strauss GM, Herndon JE, 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol. 26(31), 5043–5051 (2008).
Medline CASGoogle Scholar
8 Subramanian J, Simon R. Overfitting in prediction models – is it a problem only in high dimensions? Contemp. Clin. Trials 36(2), 636–641 (2013).
MedlineGoogle Scholar
9 Bueno R, Hughes E, Wagner S et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J. Thorac. Oncol. 10(1), 67–73 (2015).•• Presents the clinical validation of the cell cycle progression (CCP) score and combined prognostic score (CCP score + pathologic stage) as independent predictors of lung cancer death in patients with early-stage lung adenocarcinoma treated with surgery alone.
Medline CASGoogle Scholar
10 Wistuba Ii, Behrens C, Lombardi F et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin. Cancer Res. 19(22), 6261–6271 (2013).•• Validates the CCP score as a significant predictor of lung cancer death in early-stage lung adenocarcinoma treated with surgery.
Medline CASGoogle Scholar
11 Whitfield ML, Sherlock G, Saldanha AJ et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell. 13(6), 1977–2000 (2002).
Medline CASGoogle Scholar
12 Cuzick J, Swanson GP, Fisher G et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12(3), 245–255 (2011).
Medline CASGoogle Scholar
13 Clark-Langone KM, Sangli C, Krishnakumar J, Watson D. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX(®)Colon Cancer Assay. BMC Cancer 10, 691–691 (2010).
Medline CASGoogle Scholar
14 Nielsen T, Wallden B, Schaper C et al. Analytical validation of the PAM50-based prosigna breast cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 14, 177 (2014).• Presents the analytical validation of an RNA expression signature developed for formalin-fixed paraffin-embedded breast tumor tissue.
MedlineGoogle Scholar
15 Warf MB, Flake DD 2nd, Adams D et al. Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions. Biomark. Med. 9(5), 407–416 (2015).• Presents the analytical validation of an RNA expression signature developed for formalin-fixed paraffin-embedded melanocytic lesions.
CASGoogle Scholar
16 Radstrom P, Knutsson R, Wolffs P, Lovenklev M, Lofstrom C. Pre-PCR processing: strategies to generate PCR-compatible samples. Mol. Biotechnol. 26(2), 133–146 (2004).
MedlineGoogle Scholar
17 Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl. Environ. Microbiol. 63(10), 3741–3751 (1997).
Medline CASGoogle Scholar
18 Dorrie J, Wellner V, Kampgen E, Schuler G, Schaft N. An improved method for RNA isolation and removal of melanin contamination from melanoma tissue: implications for tumor antigen detection and amplification. J. Immunol. Methods 313(1–2), 119–128 (2006).
MedlineGoogle Scholar
19 Mirsadraee M, Shafahie A, Reza Khakzad M, Sankian M. Value of the polymerase chain reaction method for detecting tuberculosis in the bronchial tissue involved by anthracosis. J. Bronchology Interv. Pulmonol. 21(2), 131–134 (2014).
MedlineGoogle Scholar
20 Wang D, Wang J, Li Y, He Z, Zhang Y. The influence of anthracosis and p16 ink4a gene aberrant methylation on small-sized pulmonary adenocarcinoma. Exp. Mol. Pathol. 90(1), 131–136 (2011).
Medline CASGoogle Scholar

Vol. 9, No. 9

Metrics

Downloaded 75 times

History

Published online 9 July 2015

Published in print September 2015

Information

Keywords

Financial & competing interests disclosure

All authors are employees of Myriad Genetic Laboratories, Inc., and receive stock options and salaries as compensation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download